Mednet Logo

What adjuvant therapy would you recommend to elderly patients with pT2N0 ER-/PR-/HER2+ breast cancer?

The APT trial reported excellent DFS, OS and RFI for tumors <=3cm but few were smaller T2s (2-3 cm) and few were >70 years old.
3 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Sarah Cannon Research Institute
Answered on

Yes, I agree you are a little outside the data zone here with a T2 tumor. However, for a patient over the age of 70 with comorbidities, I think paclitaxel/trastuzumab would be a very reasonable option and many of these patients elderly patients do not do well with TCH at standard dosing. I think aft...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · University of Iowa Holden Comprehensive Cancer Center
Answered on · Updated on

APT regimen would be a reasonable consideration for an elderly with guarded PS and pT2N0, Her 2 +/ER,PR - and I agree with the above responses.

AC T-H or TCH may not be an easy regimen for an elderly unless with excellent PS.

The only other regimen I would consider in this case would be docetaxel, cyc...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · Siri Onclogy and hematology Infusion Service
Answered on

TCH with or without pertuzumab or anthracycline combinations would be very difficult to tolerate in an elderly population. What we forget is that the average age reported in these trials are not over 70, and with 4% attrition per year in an elderly population, I doubt you would show increased surviv...

Join for free or sign in to see the full answer